Lázaro Hiram Betancourt Núñez;Arielis Rodriguez Ulloa;Jeovanis Gil Valdés;Aniel Sánchez Puente;Yasser Perera Negrin;Yassel Ramos Gómez;Silvio Ernesto Perea Rodriguez;Lila Rosa Castellanos Serra;Jorge
发明人:
Silvio Ernesto Perea Rodriguez,Yasser Perera Negrin,Arielis Rodriguez Ulloa,Jeovanis Gil Valdés,Yassel Ramos Gómez,Lila Rosa Castellanos Serra,Lázaro Hiram Betancourt Núñez,Aniel Sánchez Puente,Jorge
申请号：
US12280629
公开号：
US08871725B2
申请日:
2007.02.28
申请国别(地区):
US
年份:
2014
代理人:
摘要：
This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemotherapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomicin C, imatinib, iressa and velcade (vortezomib). The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy. Furthermore, the sequential administration of this pharmaceutical combination through the pretreatment with the P15 peptide leads to the chemo sensibilization of refractory tumors to the anticancer therapeutics.
